Bionexus Gene Lab Stock Market Value
| BGLC Stock | USD 0.25 0.04 13.79% |
| Symbol | BioNexus |
BioNexus Gene Lab Price To Book Ratio
Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNexus Gene. If investors know BioNexus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNexus Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (0.06) | Revenue Per Share 0.526 | Quarterly Revenue Growth (0.23) | Return On Assets (0.10) |
The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioNexus Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNexus Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNexus Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
BioNexus Gene 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to BioNexus Gene's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of BioNexus Gene.
| 10/27/2024 |
| 11/26/2024 |
If you would invest 0.00 in BioNexus Gene on October 27, 2024 and sell it all today you would earn a total of 0.00 from holding BioNexus Gene Lab or generate 0.0% return on investment in BioNexus Gene over 30 days. BioNexus Gene is related to or competes with Oil Dri, H B, Northern Technologies, and Cabot. BioNexus Gene Lab Corporation, a molecular diagnostics company, focuses on developing and commercializing molecular diag... More
BioNexus Gene Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure BioNexus Gene's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess BioNexus Gene Lab upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.18) | |||
| Maximum Drawdown | 16.25 | |||
| Value At Risk | (5.26) | |||
| Potential Upside | 5.41 |
BioNexus Gene Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioNexus Gene's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as BioNexus Gene's standard deviation. In reality, there are many statistical measures that can use BioNexus Gene historical prices to predict the future BioNexus Gene's volatility.| Risk Adjusted Performance | (0.10) | |||
| Jensen Alpha | (0.55) | |||
| Total Risk Alpha | (1.06) | |||
| Treynor Ratio | (1.48) |
BioNexus Gene Lab Backtested Returns
BioNexus Gene Lab secures Sharpe Ratio (or Efficiency) of -0.23, which signifies that the company had a -0.23% return per unit of risk over the last 3 months. BioNexus Gene Lab exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm BioNexus Gene's Risk Adjusted Performance of (0.10), mean deviation of 2.69, and Standard Deviation of 3.49 to double-check the risk estimate we provide. The firm shows a Beta (market volatility) of 0.34, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, BioNexus Gene's returns are expected to increase less than the market. However, during the bear market, the loss of holding BioNexus Gene is expected to be smaller as well. At this point, BioNexus Gene Lab has a negative expected return of -0.89%. Please make sure to confirm BioNexus Gene's maximum drawdown, daily balance of power, relative strength index, as well as the relationship between the skewness and day typical price , to decide if BioNexus Gene Lab performance from the past will be repeated at some point in the near future.
Auto-correlation | 0.65 |
Good predictability
BioNexus Gene Lab has good predictability. Overlapping area represents the amount of predictability between BioNexus Gene time series from 27th of October 2024 to 11th of November 2024 and 11th of November 2024 to 26th of November 2024. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of BioNexus Gene Lab price movement. The serial correlation of 0.65 indicates that roughly 65.0% of current BioNexus Gene price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.65 | |
| Spearman Rank Test | 0.46 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
BioNexus Gene Lab lagged returns against current returns
Autocorrelation, which is BioNexus Gene stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting BioNexus Gene's stock expected returns. We can calculate the autocorrelation of BioNexus Gene returns to help us make a trade decision. For example, suppose you find that BioNexus Gene has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
BioNexus Gene regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If BioNexus Gene stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if BioNexus Gene stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in BioNexus Gene stock over time.
Current vs Lagged Prices |
| Timeline |
BioNexus Gene Lagged Returns
When evaluating BioNexus Gene's market value, investors can use the concept of autocorrelation to see how much of an impact past prices of BioNexus Gene stock have on its future price. BioNexus Gene autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, BioNexus Gene autocorrelation shows the relationship between BioNexus Gene stock current value and its past values and can show if there is a momentum factor associated with investing in BioNexus Gene Lab.
Regressed Prices |
| Timeline |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether BioNexus Gene Lab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNexus Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionexus Gene Lab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionexus Gene Lab Stock:Check out BioNexus Gene Correlation, BioNexus Gene Volatility and BioNexus Gene Alpha and Beta module to complement your research on BioNexus Gene. You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
BioNexus Gene technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.